Tag: rna

OXLUMO has been shown to significantly reduce urinary oxalate, which drives the progression of PH1 Disease1 MISSISSAUGA, ON, July 2, 2025 /CNW/ - Alnylam Canada ULC...

Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored by ANZUP, and supported by Bayer and...

Award is one of Houston’s most inspiring celebrations of leadership, where CEOs and visionaries are at the helm of the city’s most successful and impactful organizations

Award is one of Houston’s most inspiring celebrations of leadership, where CEOs and visionaries are at the helm of the city’s most successful and impactful organizations

Financing to accelerate commercialization of flagship products, service business, and entrance into U.S. market STOCKHOLM, June 30, 2025 /PRNewswire/ -- Epigenica AB, a pioneer in high-throughput...

In the study of rare diseases and precision medicine, understanding gene expression in the spatial context of tissues is essential. High-throughput sequencing and STOmics technology will...

Synthego Solidly Positioned for Expansion & Growth REDWOOD CITY, Calif., June 26, 2025 /PRNewswire/ -- Synthego, a leading provider of CRISPR solutions, today confirmed...

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of its lead pipeline program AX-0810 targeting NTCP, a liver cell protein that transports bile acids into cells. AX-0810 is an investigational ADAR-mediated RNA editing oligonucleotide (EON) designed to selectively modulate NTCP function by reducing toxic bile acid accumulation in the liver, potentially mitigating inflammation, fibrosis, and progression toward liver failure, which are common in cholestatic diseases.

CAMBRIDGE, England, June 26, 2025 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today...

The DHODH inhibitor market is poised for steady growth, fueled by the rising burden of autoimmune and inflammatory diseases, along with increasing interest in...

The DHODH inhibitor market is poised for steady growth, fueled by the rising burden of autoimmune and inflammatory diseases, along with increasing interest in...

IRVINE, Calif., June 24, 2025 /PRNewswire/ -- Zymo Research stole the spotlight at the American Society for Microbiology (ASM) Microbe 2025 conference with the official...

Latest Research Demonstrates Promising Improved Glucose Homeostasis by Reprogramming Alpha Cells AUSTIN, Texas, June 24, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a...